Keryx Biopharma (KERX) Announces Pivotal Ferric Citrate Phase 3 Met Primary, pre-Specified Secondary Endpoints
Tweet Send to a Friend
Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced positive top-line results for its pivotal 24-week Phase 3 study of ferric citrate, an ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
